AADAC Polyclonal Antibody
Sizes: 60μL, 120μL, 200μL
Catalogue Numbers: E-AB-14453-60, E-AB-14453-120, E-AB-14453-200
Citations, Manuals and MSDS Available upon request.
Abbreviation: AADAC
Target Synonym: AAAD; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC
Research Areas: Metabolism, Signal Transduction
Conjugation: Unconjugated
Host: Rabbit
Species Reactivity: Human
Application: WB, IHC, ELISA
Isotype: IgG
Clonality: Polyclonal
UNIProt ID: P22760
Background: Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
Concentration: 0.2 mg/mL
Immunogen: Recombinant protein of human AADAC
Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Purification Method: Affinity purification
Dilution: WB 1:500-1:2000, IHC 1:25-1:100
Calculated MW: 46kDa
Storage: -20°C/One year. Avoid freeze / thaw cycles.
Shipping: Ice bag
Research Use Only